Mentioned Users

MyMyelomaTeam

Has anyone who relapsed received Carvykti as a retreatment?

Based on available information, Carvykti (ciltacabtagene autoleucel) is approved for people with relapsed or refractory multiple myeloma who've received at least one other line of therapy and for whom lenalidomide didn't work. It's given as a single infusion and Show Full Answer

Has anyone who relapsed received Carvykti as a retreatment?

Based on available information, Carvykti (ciltacabtagene autoleucel) is approved for people with relapsed or refractory multiple myeloma who've received at least one other line of therapy and for whom lenalidomide didn't work. It's given as a single infusion and is developed specifically for each individual person.

However, the search results don't include specific information about whether people have received Carvykti as a retreatment after initially responding to it and then relapsing again. The approval was based on clinical trials showing a 98 percent overall response rate, with half of participants maintaining benefits for longer than 22 months.

Since CAR T-cell therapies like Carvykti are relatively new treatments, information about retreatment protocols is still emerging. This would be an excellent question to discuss with your doctor, as they can provide the most current information about retreatment options and whether Carvykti could be used again in your specific situation.

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

6 Refractory Myeloma Treatment Options: First Line, CAR T Cells, and More

What Is BCMA-Targeted Immunotherapy?